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In this study the effects of a new, highly selective sodium-calcium exchanger (NCX) inhibi-
tor, ORM-10962 were investigated on cardiac NCX current, Ca2+ transients, cell shortening
and in experimental arrhythmias. The level of selectivity of the novel inhibitor on several
major transmembrane ion currents (L-type Ca2+ current, major repolarizing K+ currents, late
Na+ current, Na+/K+ pump current) was also determined.
Methods
Ion currents in single dog ventricular cells (cardiac myocytes; CM), and action potentials in
dog cardiac multicellular preparations were recorded utilizing the whole-cell patch clamp
and standard microelectrode techniques, respectively. Ca2+ transients and cell shortening
were measured in fluorescent dye loaded isolated dog myocytes. Antiarrhythmic effects of
ORM-10962 were studied in anesthetized ouabain (10 μg/kg/min i.v.) pretreated guinea
pigs and in ischemia-reperfusion models (I/R) of anesthetized coronary artery occluded rats
and Langendorff perfused guinea pigs hearts.
Results
ORM-10962 significantly reduced the inward/outward NCX currents with estimated EC50
values of 55/67 nM, respectively. The compound, even at a high concentration of 1 μM, did
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not modify significantly the magnitude of ICaL in CMs, neither had any apparent influence on
the inward rectifier, transient outward, the rapid and slow components of the delayed recti-
fier potassium currents, the late and peak sodium and Na+/K+ pump currents. NCX inhibition
exerted moderate positive inotropic effect under normal condition, negative inotropy when
reverse, and further positive inotropic effect when forward mode was facilitated. In dog Pur-
kinje fibres 1 μM ORM-10962 decreased the amplitude of digoxin induced delayed afterde-
polarizations (DADs). Pre-treatment with 0.3 mg/kg ORM-10962 (i.v.) 10 min before starting
ouabain infusion significantly delayed the development and recurrence of ventricular extra-
systoles (by about 50%) or ventricular tachycardia (by about 30%) in anesthetized guinea
pigs. On the contrary, ORM-10962 pre-treatment had no apparent influence on the time of
onset or the severity of I/R induced arrhythmias in anesthetized rats and in Langendorff per-
fused guinea-pig hearts.
Conclusions
The present study provides strong evidence for a high efficacy and selectivity of the NCX-
inhibitory effect of ORM-10962. Selective NCX inhibition can exert positive as well as nega-
tive inotropic effect depending on the actual operation mode of NCX. Selective NCX block-
ade may contribute to the prevention of DAD based arrhythmogenesis, in vivo, however, its
effect on I/R induced arrhythmias is still uncertain.
Introduction
Cardiac action potential is generated by simultaneous opening and closing of a wide range of
transmembrane ion channels, as well as the activity of a number of electrogenic ion transport
mechanisms. One of the essential ion transport proteins is the sodium/calcium exchanger
(NCX) [1,2,3,4] which is a major contributor to myocardial Ca2+ homeostasis [5,6,7,8,9,10].
When the membrane potential is more negative than its equilibrium potential, NCX extrudes
Ca2+ to the extracellular space (“forward” transport mode). Since the removal of a single Ca2+
ion is paralleled with the uptake of three Na+ ions, the “forward” transport mode of the NCX
results in a net inward (i.e. depolarizing) current. If the intracellular Na+ transiently rises and
the Ca2+ level in the cell is still low and/or the membrane potential is depolarized, the NCX
operates in its “reverse” transport mode: removing three Na+ ions from, uptaking one Ca2+
ion into the cell, generating net outward (i.e. repolarizing) current [3,5,11,12,13]. Conse-
quently, during the full cardiac cycle, due to the dynamically changing membrane potential
and intracellular Na+ and Ca2+ concentrations, the transmembrane current generated by the
NCX may substantially contribute to an intracellular Ca2+-gain or loss, furthermore, due to its
electrogenic nature, it can also modulate the depolarization and repolarization processes of the
action potential [14].
Most previous studies aimed to demonstrate the antiarrhythmic effect of NCX inhibition
were based on the use of KB-R7943 and SEA-0400 [4,15,16]. However, these compounds were
shown to lack proper selectivity, since at the same concentration they efficiently inhibited
NCX current they also significantly decreased other transmembrane ionic currents, including
L-type Ca current (ICaL). This latter observation is especially important since Ca
2+-overload
generated arrhythmogenesis and pathological automaticity was shown to critically depend on
transmembrane Ca2+ movement trough ICaL [7].
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Previously, we also reported that the commonly used NCX inhibitor, SEA-0400, signifi-
cantly suppressed both delayed and early afterdepolarizations (DADs and EADs, respectively)
in dog cardiac preparations [17]. However, the selectivity of SEA-0400 for NCX versus L-type
calcium current (ICa) was found to be rather limited [18,19,20]. Recently, similar results on
EAD and DAD formation have been obtained with another novel NCX inhibitor, ORM-
10103, shown to have improved selectivity for NCX compared to SEA-0400 [21]. Although
these results reinforced the old assumption that NCX inhibition, indeed, can eliminate Ca2+
overload induced triggered arrhythmias, ORM-10103 was also found to exhibit some inhibi-
tory effect on IKr. Therefore, there was still no unambiguous experimental evidence regarding
the effects of selective NCX inhibition on cellular Ca2+-handling and cardiac action potential,
though such effects may have a major impact on both arrhythmogenic trigger and substrate
via influencing cellular Ca2+ concentration and modulating membrane voltage changes.
Since due to the lack of selective NCX inhibitors, the question how NCX inhibition may
affect cardiac arrhythmogenesis, Ca2+ handling and contraction could not be answered con-
vincingly, an alternative approach, action potential modelling has been used in order to predict
the putative effect of NCX inhibition on cardiac action potential waveform [22,23,24]. Since at
the moment our electrophysiological knowledge is rather incomplete, any result of the model-
ling work needs direct experimental validation, especially regarding such highly complex
transport systems as the NCX, critically depending on both the momentary membrane poten-
tial and intracellular Ca2+ and Na+ concentrations.
In an attempt to clarify these questions, in the present study we investigated the effects of a
novel, highly selective and effective NCX inhibitor ORM-10962 ([2-(4-hydroxy-piperidin-1-yl)-
N-(6-((2-phenylchroman-6yl)oxy)pyridin-3-yl)acetamide]; see Fig 1 for chemical structure) on
the cardiac NCX current and Ca2+ handling, and also in vivo on ouabain or ischaemia induced
cardiac arrhythmogenesis. Selectivity of the compound on L-type Ca2+ current, major repolar-
izing K+ currents, the late and peak sodium and Na+/K+ pump currents was also investigated.
Materials and Methods
Ethical statement
All experiments were carried out in compliance with the Guide for the Care and Use of Labo-
ratory Animals (USA NIH publication No 85–23, revised 1996) and were approved by the
Csongra´d County Governmental Office for Food Safety and Animal Health, Hungary
(approval No.: XIII/1211/2012). The ARRIVE guidelines were adhered to during the study,
(NC3Rs Reporting Guidelines Working Group, 2010).
Fig 1. Chemical structure of ORM-10962 [2-(4-hydroxypiperidin-1-yl)-N-(6-((2-phenylchroman-6-yl)oxy)pyridin-3-yl)acetamide].
doi:10.1371/journal.pone.0166041.g001
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Animals
Majority of measurements were performed in dog preparations. Guinea-pig papillary muscle
preparations were used for slow response experiments. In vivo guinea pigs were used for oua-
bain induced arrhythmias and rats for coronary artery occlusion induced reperfusion induced
arrhythmia studies. Guinea pigs were used for zero flow ischaemia study on Langendorff
apparatus.
Mongrel dogs of either sex weighing 8 to 16 kg, and male Sprague-Dawley CFY rats weigh-
ing 290–330 g obtained from a licensed supplier were used for the study. The experimental
animals were young adults.
Housing and husbandry
Adult mongrel dogs exclusively bred for experimental purposes (age: 24–26 months, weight:
20–25 kg; supplied by the University of Szeged Experimental Animal Facility, 6781 Domasze´k,
Tanya 701., Hungary) were used for the study. The dogs were identified by a chip implanted
subcutaneously in the neck area. All the dogs were under one roof and a common airspace,
however, each dog had its own kennel space bordered by metal bars, so that animals could
interact and see/hear each other while being safely separated. Each kennel had an “outdoor”
area (about 4 x 2 m) still under a common roof of the animal house on the top level of the
Department) and an indoor area (about 4 x 2 m) with central heating and a resting place, sepa-
rated by a trapdoor. The animals were provided various types of chew toys for enrichment. A
certified animal handler tended to the dogs every day (feeding, drinking, cleaning etc).
Male guinea-pigs (weighing 250–300 g) were kept in a separate room in groups of 6–10 in
areas divided by large wooden boards on the floor covered with wooden chips for bedding.
Each section had a surface area of 5 m2. Male Sprague-Dawley CFY rats weighing 290–330 g
were maintained in standard rat cages. All the animal house was kept at standard temperature,
humidity and lighting. The animals’ food intake and tap water consumption were provided ad
libitum. The tap water is regularly checked for any pathogens.
In vitro experiments
Voltage-clamp measurements. Cell preparations: Ventricular myocytes were enzymati-
cally dissociated from dog hearts by adapting a method described earlier in detail [21]. Follow-
ing sedation of the dogs with xylazine (1 mg/kg, i.v.) and thiopental (30 mg/kg i.v.), each heart
was rapidly removed through a right lateral thoracotomy and immediately rinsed in oxygen-
ated modified Locke’s solution containing (in mM): NaCl 120, KCl 4, CaCl2 1.0, MgCl2 1,
NaHCO3 22, and glucose 11. The pH of this solution was set between 7.35 and 7.4 when satu-
rated with the mixture of 95% O2 and 5% CO2 at 37˚C One drop of cell suspension was placed
in a transparent recording chamber mounted on the stage of an inverted microscope (Olym-
pus IX51, Olympus, Tokyo, Japan), and individual myocytes were allowed to settle and adhere
to the chamber bottom for at least 5–10 min before superfusion was initiated and maintained
by gravity. Only rod-shaped cells with clear striations were used. HEPES-buffered Tyrode’s
solution (composition in mM: NaCl 144, NaH2PO4 0.4, KCl 4.0, CaCl2 1.8, MgSO4 0.53, glu-
cose 5.5 and HEPES 5.0, at pH of 7.4) served as the normal superfusate.
Recording procedures: Micropipettes were fabricated from borosilicate glass capillaries (Sci-
ence Products GmbH, Hofheim, Germany), using a P-97 Flaming/Brown micropipette puller
(Sutter Co, Novato, CA, USA), and had a resistance of 1.5–2.5 MOhm when filled with pipette
solution (composition detailed later). The membrane currents were recorded with Axopatch-
200B amplifiers (Molecular Devices, Sunnyvale, CA, USA) by means of the whole-cell configu-
ration of the patch-clamp technique. The membrane currents were digitized with 250 kHz
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analogue to digital converters (Digidata 1440A, Molecular Devices, Sunnyvale, CA, USA)
under software control (pClamp 10, Molecular Devices, Sunnyvale, CA, USA). Experiments
were carried out at 37˚C. For measuring the currents we applied relative similar voltage proto-
cols as described earlier in details, however, many of them were partially adapted for focused
reasons [21,25,26].
Measurement of NCX current: For the measurement of the Na+/Ca2+ exchanger current
(INCX), the method of Hobai et al [27] was applied. Accordingly, the NCX current is defined as
Ni2+-sensitive current and measured in a special K+-free solution (composition in mM: NaCl
135, CsCl 10, CaCl2 1, MgCl2 1, BaCl2 0.2, NaH2PO4 0.33, TEACl 10, HEPES 10, glucose 10
and ouabain 20 μM, nisoldipine 1 μM, and lidocaine 50 μM, at pH 7.4) as described earlier
[21] in detail. The pipette solution used for recording INCX contained (in mM) CsOH 140,
aspartic acid 75, TEACl 20, MgATP 5, HEPES 10, NaCl 20, EGTA 20 and CaCl2 10, pH
adjusted to 7.2 with CsOH.
Measurement of L-type calcium current (ICaL): The L-type calcium current (ICaL) was
recorded in HEPES-buffered Tyrode’s solution supplemented with 3 mM 4-aminopyridine. A
special solution was used to fill the micropipettes (composition in mM: KOH 40, KCl 110,
TEACl 20, MgATP 5, EGTA 10, HEPES 10 and GTP 0.25, pH was adjusted to 7.2 by KOH).
Measurement of potassium currents: The inward rectifier (IK1), transient outward (Ito),
rapid (IKr) and slow (IKs) delayed rectifier potassium currents were recorded in HEPES-buff-
ered Tyrode’s solution. The composition of the pipette solution (in mM) was the following:
KOH 110, KCl 40, K2ATP 5, MgCl2 5, EGTA 5, HEPES 10 and GTP 0.1 (pH was adjusted to
7.2 by aspartic acid). 1 μM nisoldipine was added to the bath solution to block ICaL. When IKr
was recorded, IKs was inhibited by using the selective IKs blocker HMR 1556 (0.5 μM). During
IKs measurements, IKr was blocked by 0.5 μM dofetilide and the bath solution contained
0.1 μM forskolin.
Since the run-down of ICaL and IKs currents is commonly seen during the measurements,
the current level was monitored during the initial equilibration period and also at the end of
the measurements when a washout period of at least 10 min was applied in order to draw a dis-
tinction between drug effect and rundown of the current. The cells, in which excessive run-
down was observed, were omitted from the analysis.
Measurement of late sodium current (INaL): The sodium current was activated by depolar-
izing voltage pulses to -20 mV from the holding potential of -120 mV. After 5–7 min incuba-
tion with ORM-10962 the external solution was replaced by that containing 20 μM TTX. TTX
at this concentration completely blocks the late sodium current (INaL). The external solution
was HEPES-buffered Tyrode’s solution supplemented with 1 μM nisoldipine, 0.5 μM HMR-
1556 and 0.1 μM dofetilide in order to block ICaL, IKs and IKr currents. The composition of the
pipette solution (in mM) was: KOH 110, KCl 40, K2ATP 5, MgCl2 5, EGTA 5, HEPES 10 and
GTP 0.1 (pH was adjusted to 7.2 by aspartic acid).
All of the voltage clamp data that is presented is normalized to the capacity of the cell and is
expressed as current density (pA/pF). When concentration-dependent effect of ORM-10962
on NCX current was measured the concentration of the drug was expressed as the log10 of
concentration in Mol to follow the usual procedure.
Measurement of peak sodium current (INa) in CHO cells: cDNA clone of the cardiac
sodium channel Nav1.5 was provided by Gyo¨rgy Panyi [28] and was heterologously over-
expressed in Chinese hamster ovary cells (CHO; ATCC, Manassas, Virginia,USA). CHO cells
were cultured in F12 medium (Lonza, Verniers, Belgium) supplemented with 10% fetal bovine
serum (PAA, Paschling, Austria) at 37˚C in a humidified atmosphere containing 5% CO2.
Transient transfections were carried out as follows. CHO cells were plated one day before trans-
fection in 60 mm diameter culture dishes. 2 μg of the Nav1.5 plasmid DNA, 1 μg green
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fluorescent protein (GFP) over-expressing plasmid and 20 μg polyethylenimine (25kDa, linear,
Polysciences Inc., PA, USA) were combined in 1.5 ml serum-free F12. The transfection mixture
was incubated at room temperature for 30 minutes, during which time the cells were washed
with serum-free F12 twice. After washing, the transfection mixture was added to the cells and
the culture dishes were moved back into the CO2 incubator for 2 hours. At the end of the incu-
bation period, the transfection mixture was replaced by growth medium. Plasmid samples used
in the transfections were purified by Nucleobond PC100 anion-exchange columns (Macherey-
Nagel GmbH & Co. KG, Du¨ren, Germany). 48 hours post-transfection the cells were briefly
trypsinized, collected by centrifugation and were re-suspended in growth medium.
Transfected CHO cells were replaced in the bath and superfused with HEPES-buffered Tyr-
ode’s solution. Inverted fluorescent microscope (Olympus IX51) allowed for visualisation of
the GFP fluorescence. The electrodes were filled with the pipette solution (in mM): KOH 110,
KCl 40, K2ATP 5, MgCl2 5, EGTA 5, HEPES 10 and GTP 0.1 (pH was adjusted to 7.2 by aspar-
tic acid). In GFP positive cells the sodium peak current was recorded at room temperature
(~23˚C). Capacitance of cells was cancelled and series resistance was compensated to 70–80%.
Current was elicited by step pulse to -20mV for 20ms from the holding potential of -90mV.
Measurement of Na+/K+ pump current: Steady-state current at -30 mV was recorded in
control conditions and in the presence of ORM-10962. After 5–7 min incubation with ORM-
10962 the normal external solution (composition in mM: NaCl 135, CsCl 2, KCl 5, MgCl2 1,
CdCl2 0.2, BaCl2 2, HEPES 5, glucose 10, pH 7.4 by NaOH) was replaced by K
+ free solution.
The Na+/K+ pump current (Ip) was defined as the difference between currents measured in
5mM K+ and in 0 mM K+ containing solutions. The composition of the pipette solution (in
mM) was: CsOH 100, aspartic acid 100, NaCl 30, MgATP 5, MgCl2 2, TEACl 20, EGTA 5,
HEPES 10 and glucose 10 (pH was adjusted to 7.2 by CsOH).
Action potential measurements with standard microelectrode technique. Recording of
delayed afterdepolarizations: For measuring action potentials we applied relative similar pro-
tocols as described earlier in detail, however, many of them were partially adapted for focussed
reasons [21,25,26].
The same adult mongrel dogs of either sex weighing 8–16 kg were used. Purkinje strands
obtained from both ventricles and right ventricular papillary muscle tips were mounted indi-
vidually in a tissue chamber superfused with oxygenated Locke’s solution at 37˚C. Each prepa-
ration was stimulated (HSE stimulator type 215/II), initially at a constant cycle length of 1000
ms (frequency 1 Hz), with rectangular constant current pulses 2 ms in duration. The current
pulses were isolated from ground and delivered through bipolar platinum electrodes in contact
with the preparations. At least 1 h was allowed for each preparation to equilibrate during con-
tinuous superfusion with modified Locke’s solution, warmed to 37˚C before the experimental
measurements commenced. Transmembrane potentials were recorded with the use of conven-
tional 5–20 MO, 3 M KCl-filled microelectrodes connected to the input of a high-impedance
electrometer (Biologic Amplifier VF 102, Claix, France). The first derivative of transmembrane
potential (dV/dtmax) was obtained electronically with a Biologic DV-140 (Claix, France) differ-
entiator designed and calibrated to give a linear response over the range between 10 and 1000
V/s. In each experiment, the baseline action potential characteristics were first determined
during continuous pacing at 1 Hz (on Purkinje fibres, continuous pacing at 2 Hz), and then
when the pacing cycle length was sequentially varied from 300 to 5000 ms. The 25th action
potential was measured at each cycle length, and the cycle length was then changed so that
quasi-steady-state frequency-response relations could be generated rapidly. The preparations
were next superfused with the drug for 40–60 min before the pacing protocol was repeated
and the parameters were measured again. Efforts were made to maintain the same impalement
throughout each experiment. If an impalement became dislodged, however, electrode
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adjustment was attempted and, if the action potential characteristics of the re-established
impalement deviated by less than 5% from those of the previous measurement, the experiment
was continued. When this 5% limit was exceeded, the experiment was terminated and all the
data involved were excluded from the analyses.
Recording of slow response action potentials: Adult guinea-pigs of either sex weighing 250–
300 g were anticoagulated with sodium-heparin and anaesthetized with 30 mg/kg i.v. thiopental
after sedation (xylazine, 1 mg/kg i.v.). The hearts were rapidly removed through a right lateral
thoracotomy and immediately rinsed in ice-cold Krebs-Henseleit solution (containing in mM:
NaCl 118.5, KCl 4.0, CaCl2 2.0, MgSO4 1.0, NaH2PO4 1.2, NaHCO3 25.0 and glucose 10.0). The
pH of this solution was set to 7.35±0.05 when saturated with a mixture of 95% O2 and 5% CO2.
After excision, the right or left ventricular papillary muscle preparations were immediately
mounted in a 40 ml tissue chamber, and initially perfused with normal Krebs-Henseleit solution.
The preparations were stimulated (Experimetria Ltd, PW-01, Hungary) by means of con-
stant rectangular voltage pulses (1 ms) delivered through a pair of bipolar platinum electrodes
at a frequency of 1 Hz. Action potentials were recorded with a conventional microelectrode
technique. Sharp microelectrodes, with a tip resistance of 10–20 MO when filled with 3 M KCl,
were connected to the amplifier (Biologic Amplifier, model VF 102). The voltage output from
the amplifier was sampled with an AD converter (NI 6025, Unisip Ltd, Hungary). The action
potential amplitude and maximum rate of depolarization were obtained with Evokewave v1.49
software (Unisip Ltd, Hungary). Each preparation was allowed for at least 30 min to equilibrate
in normal Krebs-Henseleit solution at 37˚C.
Slow response action potentials were established in modified Krebs-Henseleit solution con-
taining 25 mM KCl, supplemented with 100 μM BaCl2 to inhibit IK1 and with 1 μM forskolin
to increase ICaL. dV/dtmax values in the interval 5–20 V/s, and amplitudes of at least 60 mV
were accepted; data from experiments in which these levels were not met were discarded.
Measurements of [Ca2+]i transients and cell shortening. For measuring fluorescent
optical signals, isolated dog ventricular myocytes were used loaded with a Ca2+ sensitive dye
Fluo-4AM for 20 minutes in room temperature in dark. One drop of the loaded cells were
placed in a cell chamber (RC47FSLP, Warner Instruments, Hamden, CT, USA) and were field
stimulated at 1 Hz (PW-01, Experimetria Ltd. Hungary). The measurement was performed on
an inverted microscope (Olympus IX 71; Olympus Cor-poration, Tokyo, Japan). The fluores-
cent dye was excited at 480 nm and emitted at 535 nm. Ca2+ signals were recorded by a photon
counting photomultiplier module (Hamamatsu, model H7828; Hamamatsu Photonics
Deutschland GmbH, Herrsching am Ammersee, Germany) and were digitized and sampled at
1 kHz by using Digidata 1440A interface (Axon Instruments). The data acquisition and analy-
sis were performed by Clampex 10.0 and Clampfit 10.0 (Axon Instruments). The transient
amplitudes were calculated as a difference of the peak and diastolic fluorescent values. Back-
ground fluorescence levels were used to correct raw fluorescence data. The Ca2+ transients
were normalized to the diastolic fluorescent level. The cell shortening was measured by using a
video edge detector system (VED-105, Crescent Electronics, Sandy, UT, USA).
The control transients were monitored in a normal HEPES-buffered Tyrode’s solution
(containing in mM: 144 NaCl, 0.4 NaH2PO4, 4 KCl, 0.53 MgSO4, 1.8 CaCl2, 5.5 glucose and 5
HEPES; pH was adjusted to 7.4 with NaOH) then were switched to modified Tyrode’s solution
containing 70 mM NaCl and 70 mM cholin-cloride or normal Tyrode’s solution supplemented
with 600 nM forskolin depending on the experimental group. After recording the control tran-
sients, 1 μM ORM-10962 were added to the solution.
Statistical analysis. All data are expressed as means ± standard error (SEM). Statistical
analysis was performed with Student’s t-test for paired data. The results were considered statis-
tically significant when P was < 0.05.
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In vivo experiments
Male guinea pigs and Sprague-Dawley CFY rats were investigated in ouabain induced and
ischaemia-reperfusion induced arrhythmia models, respectively. Animals were fed with stan-
dard chow for rodents (Szindba´d Ltd., Go¨do¨llő, Hungary) and were allowed to drink tap water
ad libitum. 12h dark/light cycles were maintained.
The outcome of the mortality during the experiments was in agreement with that of antici-
pated such that it was reviewed and approved by the animal ethics committee as part of our
approved protocol.
Ouabain induced arrhythmias. The methods described earlier by others [29,30] were
applied. Male guinea-pigs, weighing 320-440g, were anaesthetized with pentobarbitone (45
mg/kg intraperitoneally). The trachea was prepared and cannulated in order to maintain artifi-
cial respiration (under room air, volume 1.5 ml/100g at a rate of 35 strokes/min, Harvard
Rodent Ventilator 683, South Natick, MA, USA). The ECG (lead II) was continuously
recorded and the arterial blood pressure was measured in the right arteria carotis communis
(PowerLab 8 SP, ADInstrument). The left vena jugularis was cannulated for the drug adminis-
tration and ouabain infusion. ORM-10962 (solved in DMSO: isotonic saline, 1:9) was adminis-
tered in bolus 10 minutes before starting ouabain infusion. The control group received the
solvent of the drug. Ouabain was continuously infused (at the rate of 10 μg/kg/min using an
infusion pump (Terumo, TE-331), at the rate of 6ml/h/kg, intravenously.
In another series of experiments the suspension of ouabain induced arrhythmias by ORM-
10962 was investigated. Ouabain (10 μg/kg/min) was infused for 16 min. ORM-10962 was
administered intravenously after the termination of ouabain infusion and the ECG and blood
pressure changes were recorded, as described above.
Myocardial ischaemia-reperfusion induced arrhythmias in rat. Male Sprague-Dawley
rats were used. Coronary artery occlusion and reperfusion were performed as described previ-
ously [31,32]. During pentobarbitone anaesthesia (60 mg/kg intraperitoneally) the chest was
opened between the fourth and fifth ribs and the heart was exposed. A loose loop of atraumatic
silk (4/0 Mersilk black, W582, Ethicon) was placed around the left main coronary artery. After
the surgery artificial respiration was started (at a rate of 60 strokes/min, volume 1.4 ml/min,
Harvard Rodent Ventilator 683, South Natick, MA, USA). After 10 minutes normalization the
coronary artery was occluded by tightening the loop for 6 minutes, followed by reperfusion for
5 minutes. Arterial blood pressure was measured via the right arteria carotis communis. The
left vena femoralis was prepared and cannulated for drug administration. Solution of ORM-
10962, as described previously, was administered 10 minutes before the coronary artery occlu-
sion. ECG lead II was registered in both protocols. Heart rate and the time to the development
of ventricular arrhythmias were measured on the ECG.
Myocardial ischaemia-reperfusion induced arrhythmias in guinea-pig. Male guinea
pigs weighing 300-400g were used. Animals were anaesthetized with sodium-pentobarbital
(300mg/kg, i.p.) and injected with heparin sodium (300 IU, ip.). Hearts were rapidly
excised, mounted via the aorta on a Langendorff apparatus and retrogradely perfused with
warm (37˚C), modified Krebs–Henseleit bicarbonate (KHB) buffer at a constant pressure
(80 mmHg). The KHB solution contained (in mmol/L): NaHCO3 25; KCl 4.3; NaCl 118.5;
MgSO4 1.2; KH2PO4 1.2; glucose 10; CaCl2 1.8, having a pH of 7.4±0.05 when gassed with
95% O2 + 5% CO2. Ventricular fibrillations were induced by reperfusion following 20 min-
utes zero flow ischemia. The ECG was recorded using the WinWCP software (V4.9.1.
Whole Cell Electrophysiology Analysis Program, John Dempster, University of Strathclyde,
UK).
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The animals (rats and guinea pigs) that during the in vivo experiments did not die from
irreversible ventricular fibrillation were euthanized at the end of investigational protocol by
overdosing anaesthetic drug (pentobarbitone).
Statistical analysis. Parameters were expressed as means ± SEM. and after analysis of var-
iance (one-way ANOVA) groups were compared in pairs by means of the modified “t-statis-
tics” of Wallenstein et al [33]. The survival rate was compared by using the Chi-square test.
Materials
With the exception of ORM-10962 (from Orion Pharma, Espoo, Finland), nisoldipine (gift
from Bayer AG, Leverkusen, Germany) and HMR-1556 (gift from Aventis Pharma, Frankfurt,
Germany) all chemicals were purchased from Sigma-Aldrich Fine Chemicals (St. Louis, MO,
USA) or Sequoia Research Products Ltd (Pangbourne, UK). ORM-10962 was dissolved in
DMSO to yield a 1 mM stock solution. This stock solution was diluted to reach the desired
final concentration (DMSO concentration not exceeding 0.1%) in the bath.
Results
Effects of ORM-10962 on the outward and inward NCX current
INCX was measured as Ni
2+ sensitive current using voltage ramp waveforms for the command
potential (Fig 2). The protocol adapted from Hobai et al [27] was described earlier in detail
[21]. Current traces were recorded after blocking Na+, Ca2+, K+ and Na+/K+ pump currents.
Then, ORM-10962 was applied and the current was recorded with the same voltage waveform.
Finally, 10 mM NiCl2 was added to the bath solution for the complete blockade of the NCX
current and this trace was subtracted from the control record and from the ORM-10962 record
resulting in Ni2+ sensitive current traces in control conditions and in the presence of ORM-
10962 (Fig 2).
Fig 3 illustrates that ORM-10962 decreased the NCX current in a concentration-dependent
manner with estimated IC50 values of 55 and 67 nM at -80 and at 20 mV, respectively (Fig 3).
Under the conditions of our experiments, putative exchange currents reversed as expected
about -30 mV, and the currents were decreased without a change of reversal potential by
ORM-10962. We did not examine specifically whether the compound might inhibit preferen-
tially the outward or inward current modes under conditions that would maximize the unidi-
rectional exchanger operation.
Selectivity of ORM-10962
The possible effect of ORM-10962 on the L-type calcium (ICaL) current was investigated in sin-
gle dog ventricular myocytes. The current was activated by 400 ms depolarizing voltage pulses
to potentials ranging from -35 mV to 55 mV. The holding potential was -80 mV. A prepulse to
-40 mV served to inactivate sodium current. These experiments showed that ORM-10962 even
at high (1 μM) concentration did not block ICaL (Fig 4A). Though, after application of ORM-
10962 a small but significant decrease of the current occurred, after wash out of the drug the
current further decreased, which revealed that the slight reduction of the current amplitude in
the presence of ORM-10962 was the consequence of the run-down phenomenon.
Since the ICaL measurements in same experiments exhibited a small run-down in some volt-
age clamp experiments, the effect of ORM-10962 was also studied on slow response action
potentials recorded from guinea-pig papillary muscles. As Fig 4B shows, ORM-10962 at 1 μM
(a concentration about 20 fold higher than the IC50 for NCX inhibition) did not affect the
amplitude (control: 73.2±0.7 mV, ORM-10962: 72.1±4.9 mV, n = 5, n.s.) or dV/dtmax (control:
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17.6±0.7 V/s, ORM-10962: 16.6±0.9 V/s, n = 5, n.s.) of these slow response action potentials,
suggesting the lack of effect of ORM-10962 on the L-type calcium current. In the same prepa-
rations the well-established calcium current blocker nisoldipine at 100 nM markedly reduced
both the amplitude and dV/dtmax of the slow response action potentials (73.2±0.7 mV vs 44. 2
±1.5 mV and 17.6±0.7 V/s vs 5.9±1.5 V/s, respectively; n = 5, p<0.05).
The possible effect of ORM-10962 on INaL current was also studied in dog left ventricular
myocytes. Fig 5A illustrates that addition of 1 μM ORM-10962 did not decrease the amplitude
of INaL, while 20 μM TTX completely blocked the current. The amplitude of the TTX sensitive
INaL was -0.63±0.13 pA/pF in control conditions and -0.65±0.14 pA/pF after application of
1 μM ORM-10962 (n = 5, n.s.). The possible effect of ORM-10962 on peak INaL was measured
in Nav1.5 expressing CHO cells (Fig 5B). Under control conditions the current was not signifi-
cantly changed (-806.6±299.3 pA/pF vs. -782.7±257 pA/pF after 1 μM ORM-10962; Δ = 1.06
±0.04%). The application of 20 μM TTX markedly reduced the current magnitude to 152.8
±47.9 pA/pF (Δ = 79.6±0.01%; n = 10, p<0.05).
The Na+/K+ pump current (Ip) was 0.46±0.10 pA/pF in control conditions and it decreased
to 0.39±0.11 pA/pF (16.2%, n = 5, p<0.05) at the end of the 5–7 min incubation with 1 μM
ORM-10962. During these measurements a gradual slight decrease of the steady-state current
was observed (Fig 5C). Therefore, a separate set of experiments was performed when the same
protocol was applied but ORM-10962 was not added to the bath solution. Measuring the
Fig 2. Determination of NCX current in dog ventricular myocytes. The protocol was adapted from Hobai et al [27]. A: Recording
obtained with the voltage protocol shown in the inset in control conditions (current trace after blockade of Na+, Ca2+, K+ and Na+/K+ pump
currents. B: The current trace after superfusion with 100 nM ORM-10962. C: The current trace at the end of the measurements after the
application of 10 mM NiCl2. On the right the control NCX current is shown, which is obtained by subtracting trace C from trace A. The NCX
current in the presence of 100 nM ORM-10962 is obtained by subtracting trace C from trace B. Note the difference in the intensity-time
calibration in the left and right panels.
doi:10.1371/journal.pone.0166041.g002
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steady-state current at the same time scale, comparing to the ORM-10962 experiments, a simi-
lar small current decrease was recorded (0.55±0.10 pA/pF vs 0.44±0.06 pA/pF, 21.5%, n = 3,
n.s., Fig 5C). Therefore, it is concluded that ORM-10962 does not influence Ip, the slight ten-
dency of the current to decrease is not due to the effect of ORM-10962. In another experiment,
10 μM strophanthin, known to block Na+/K+ pump was applied. Strophanthin effectively
diminished the current and 0 K+ solution failed to decrease the current further showing that
the measured current is Na+/K+ pump current (Fig 5C).
The effect of ORM-10962 on the four main repolarizing potassium currents, IK1, Ito, IKr and
IKs currents was also investigated. Inward rectifier potassium current (IK1) was measured by
determining the steady-state current at the end of 300 ms long pulses clamped to potentials
ranging from -80 to 0 mV. The pulse frequency was 0.33 Hz (Fig 6A). Transient outward
potassium current (Ito) was activated by 1000 ms long depolarizing voltage pulses arising from
the holding potential of -80 mV to test potentials gradually increasing up to 50 mV. The pulse
frequency was 0.33 Hz (Fig 6B). The rapid and slow components of the delayed rectifier potas-
sium currents (IKr and IKs) were determined as tail current amplitudes at -40 mV after activat-
ing these currents by 1000 ms (IKr) or 5000 ms (IKs) long depolarizing voltage pulses of various
Fig 3. The concentration-dependent effect of ORM-10962 on the NCX current in dog ventricular myocytes. Panel A. Original
Ni2+-sensitive (NCX) current traces before and after superfusion of the cells with ORM-10962 at concentrations of 10 nM, 100 nM and 1 μM.
Panel B. The drug-response curve of ORM-10962 on the outward (top) and inward (bottom) NCX currents in dog ventricular myocytes is
given at 20 mV and at -80 mV, respectively. Values are means ± SEM. Numbers in brackets show the number of experiments for each data
point.
doi:10.1371/journal.pone.0166041.g003
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test potentials ranging up to 50 mV. The pulse frequency was 0.05 Hz or 0.1 Hz, respectively. It
was found that neither of these currents was significantly affected by 1 μM ORM-10962 (Figs 6
and 7).
Effect of NCX inhibition on Ca2+ transient, cell shortening, and action
potentials
The effect of 1 μM ORM-10962 on Ca2+ transients and cell shortening were studied simulta-
neously on isolated dog ventricular myocytes. The myocytes were field stimulated at 1 Hz. In
these experiments 3 groups were separated.
In the “physiological NCX operational mode” we recorded the baseline Ca2+ transients and
cell shortening in normal Tyrode’s solution then the perfusion was switched to normal Tyr-
ode’s solution containing 1 μM ORM-10962 (Fig 8A and 8C). Under control condition the
Fig 4. Panel A. Lack of effect of 1 μM ORM-10962 on the L-type ICa in dog ventricular myocytes. The panel illustrates original ICaL current
traces before and after application of 1 μM ORM-10962 (left panel) and the corresponding current-voltage relationship of ICaL in the absence
and presence of 1 μM ORM-10962, as well as after washout of ORM-10962 on an average of 7 myocytes. Values are means ± standard
errors of the means, n = 7, *p<0.05. Insets show the applied voltage protocols. Panel B. Lack of significant effect of ORM-10962 on slow
response action potentials in guinea-pig ventricular myocytes. Original slow action potential records under control conditions, in the
presence of 1 μM ORM-10962 and after application of 100 nM nisoldipine (left). Bar diagrams (right) reveal the lack of effect of 1 μM ORM-
10962 on the action potential amplitude and on the maximum rate of depolarization (dV/dtmax), respectively. Values are means ± SEM, n = 5.
*P<0.05.
doi:10.1371/journal.pone.0166041.g004
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amplitude of Ca2+ transients and cell shortening increased only slightly but statistically signifi-
cantly (Ca2+ transients: 15.03±2.16 AU vs 15.48±2.10 AU Δ = 3.80±1.49%, n = 8, p<0.005;
Cell shortening: -2.03±0.92 AU vs. -2.35±1.05 AU, Δ = 15.59±3.01%, n = 8, p<0.05). The dia-
stolic Ca2+ did not change significantly during the experiment. The characteristic of the action
potential did not change after application of 1 μM ORM-10962 (APD90: 218.4±10.85 ms vs
222.5±9.66 ms; Δ = 1.86±1.55%; n = 8; Fig 8B and 8C).
In the enhanced reverse NCX operational mode group, the NaCl was reduced to 70 mM
while the solution was supplemented with 70 mM choline-cloride. Under this condition the
Ca2+ transients and cell shortening increased by the administration of low Na-Tyrode, and sig-
nificantly decreased when 1 μM ORM-10962 was applied (Fig 9A). Ca2+ transients under con-
trol condition: 8.47±0.83 AU! low Na+: 11.53±2.50 AU! 1 μM ORM-10962: 9.46±1.98
AU; n = 5, p<0.05. The transient amplitude decrease after ORM-10962 application was
Fig 5. Panel A. Lack of effect of ORM-10962 on INaL current in dog ventricular myocytes. Original current traces show that 1 μM ORM-
10962 does not influence INaL, while 20 μM TTX blocks the current. The applied voltage protocol is illustrated on the top of the Figure. Panel
B. Lack of effect of 1 μM ORM-10962 on peak INa measured in Nav1.5 expressed chinese hamster ovary (CHO) cells. The ORM-10962 did
not influence the current (red line and bar), while 20μM TTX significantly reduced the current (blue line and bar). The applied voltage protocol
is illustrated on the top of the Figure. Panel C. Lack of effect of ORM-10962 on Na+/K+ pump current. Top trace shows that 1 μM ORM-
10962 does not influence Ip, however, a slight gradual decrease of the current was detected. An original current record in the middle trace
indicates that the slight gradual current decrease, similar to that shown in the top trace, was also observed without addition of ORM-10962.
Bottom trace: Strophanthin (10 μM) completely blocks Na+/K+ pump current. Ip was defined as the difference between currents measured in
5 mM K+ and in 0 mM K+ containing solutions. The current traces were recorded at a steady potential of -30 mV.
doi:10.1371/journal.pone.0166041.g005
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-16.07±5.77%. The results of cell shortening measurements were the following: control: -3.80
±1.4 AU! low Na+: -6.61±2.18 AU! 1 μM ORM-10962: -4.01±1.79 AU; n = 5, p<0.05.
The decrease of cell shortening was -38.12±16.45% after ORM-10962 application. The dia-
stolic Ca2+ significantly decreased after ORM-10962 application (vs. low Na+): 31.8±3.9 AU vs
28.6±2.9 AU; n = 5, p<0.05). Under this condition the APD90 of the action potential slightly
but statistically significantly increased during ORM-10962 administration vs. 70 mM NaCl-
contained Tyrode solution (184.5±10.4 ms vs 205.0±7.3 ms; n = 6, p<0.05; Fig 9B).
In the enhanced forward NCX operational mode group the normal Tyrode solution was sup-
plemented with 600 nM forskolin which increased the amplitude of transient and cell shorten-
ing. Application of 1 μM ORM-10962 increased further the amplitudes significantly (Fig 9C).
Ca2+ transients under control condition: 15.89±1.82 AU! 600 nM forskolin: 13.72±1.50 AU
! 1 μM ORM-10962: 16.21±1.80 AU; n = 5, p<0.05. The increase of transient amplitude was
18.3±3.13% after ORM-10962 application. Cell shortening under control condition: -2.56
±0.49 AU! 600 nM forskolin: -3.64±0.81 AU! 1 μM ORM-10962: -5.43±1.14 AU; n = 5,
p<0.05. The increase of cell shortening amplitude was 56.47±17.85% after ORM-10962
Fig 6. Lack of effect of ORM-10962 on the inward rectifier potassium and transient outward potassium currents (IK1 and Ito) in dog
ventricular myocytes. Panels A and B. Original IK1 (top) and Ito (bottom) current traces (left panels) recorded under control conditions and
in the presence of 1 μM ORM-10962, and the corresponding I-V current-voltage relationships (right panels) before and after application of
1 μM ORM-10962, respectively. The insets in the I-V diagrams show the voltage protocol applied during measurements. Values represent
means ± SEM, n = 8 and 10, respectively.
doi:10.1371/journal.pone.0166041.g006
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application. The diastolic Ca2+ did not change significantly during the experiment. The effect
of these conditions on the transient and cell shortening amplitude is depicted in Fig 9E as bar
graph. Under this condition the APD90 of the action potential did not change significantly,
however the mid-plateau potential was significantly reduced (9.7±2.2 mV vs 3.7±2.9 mV;
n = 6, p<0.05; Fig 9D).
Effect of NCX inhibition on in vitro triggered arrhythmias
The effects of ORM-10962 on delayed (DAD) afterdepolarizations were studied in dog cardiac
Purkinje fibres by applying the conventional microelectrode technique. DAD was evoked in
Purkinje fibre preparations superfused with 150 nM digoxin for 40 min (Fig 10A, left and mid
panels). In these experiments, a train of 40 stimuli was applied with a cycle length of 400 ms in
the train. The train was then followed by a stimulation-free period of 20 s to allow the observa-
tion of DAD formation. Following addition of 1 μM ORM-10962, the DAD amplitude was
decreased (from 5.3±0.7 mV to 1.5±0.3 mV; n = 8, p<0.05; Fig 10A, right panel).
Fig 7. Lack of effect of ORM-10962 on the rapid and slow delayed rectifier outward potassium currents (IKr and IKs) in dog
ventricular myocytes. Panels A and B. Original IKr (top) and IKs (bottom) current traces (left panels) recorded under control conditions and
in the presence of 1 μM ORM-10962, and the corresponding I-V current-voltage relationships (right panels) before and after application of
1 μM ORM-10962, respectively. The insets in the I-V diagrams show the voltage protocol applied during measurements. Values represent
means ± SEM, n = 6 and 6, respectively.
doi:10.1371/journal.pone.0166041.g007
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In six from 8 experiments, digoxin evoked a run of extra beats (cellular corresponding of
the in vivo extrasystole) after the termination of the stimulus train, which could be successfully
abolished by the application of 1 μM ORM-10962 (Fig 10B).
Effect of NCX inhibition on in vivo triggered arrhythmias
Prevention of ouabain induced arrhythmias by ORM-10962 in guinea-pigs. Intrave-
nous infusion of ouabain (10μg/kg/min) induced ventricular arrhythmias such as extrasystole,
bigeminia, tachycardia, ventricular fibrillation and AV block in guinea-pigs. In the control
group the first arrhythmias developed around the 24th minute. Seven-eight minutes later ven-
tricular tachycardia appeared, that was followed by fibrillation around the 37th minute after
starting ouabain infusion. ORM-10962 (0.3 mg/kg) pre-treatment (i.v. 10 min before starting
Fig 8. Ca2+ transients and cell shortening were simultaneously measured in isolated dog ventricular myocytes under normal conditions
(panel A). The cells were loaded with Fluo-4AM fluorescent dye, and were field stimulated at 1 Hz. A small, but statistically significant
increase in the transient and cell shortening magnitude was measured after application of 1 μM ORM-10962 (red line). The action potentials
were measured by using the conventional microelectrode technique in dog right papillary muscles. In this case 1 μM ORM-10962 failed to
influence the action potential characteristic (Panel B). The effects of ORM-10962 on Ca2+ -transient amplitude (white column), cell
shortening (black column) and on APD90 (gray column) were compared in bar graph, depicted in Panel C.
doi:10.1371/journal.pone.0166041.g008
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ouabain infusion) significantly delayed the development of ventricular extrasystoles (from 24
±1.7 min in controls to 36.6±2.7 min in the presence of the drug, p<0.05) or ventricular
tachycardia (from 31.8±1.8 min in controls to 40.8±2.1 min in the presence of the drug,
p<0.05; Table 1 and Fig 11A).
There were no significant differences in the heart rate, systolic- and diastolic blood pressure
(SP and DP) among the groups before the drug administration (-10 min). As a result of oua-
bain infusion heart rate and blood pressure increased. In the control group the last measured
time-point was at the 19th minute, because 24 minutes after the beginning of ouabain adminis-
tration extrasystoles are already developed, followed by more serious ventricular tachycardia
and fibrillation, until the death of the animal. ORM-10962 pre-treatment: i) did not induce sig-
nificant effect on the basal heart rate and blood pressure; ii) delayed the blood pressure
increasing effect of ouabain and the appearance of arrhythmias. Hence, the last measured pres-
sure values before the beginning of the arrhythmias were at the 30th minute (Table 2).
Fig 9. Panel A shows representative Ca2+ transient tracings and cell shortenings when NCX reverse mode was facilitated by reduction of
the external NaCl to 70 mM. Under this setting, the application of 1 μM ORM-10962 significantly decreased the magnitude of Ca2+ transient
(red line) and cell shortening (red line) compared to 70 mM NaCl containing Tyrode’s solution (black lines). In this case the APD90 of the
action potential was slightly increased (Panel B). The forward mode of NCX was increased by 600 nM forskolin (Panel C). Under this setting
1 μM ORM-10962 further increased the amplitudes of the transient and cell shortening (red lines). The mid-plateau potential of the action
potential significantly decreased (Panel D). The change of Ca2+ transient and cell shortening under reverse (black column) and forward
mode (grey column) enhancement were depicted by bar graphs in Panel E.
doi:10.1371/journal.pone.0166041.g009
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Suspension of ouabain induced arrhythmias by ORM-10962 in guinea-pigs. Intrave-
nous infusion of ouabain (10μg/kg/min) did not produce severe arrhythmias during the 16
min infusion. Only 9 out of 22 animals developed sporadic ventricular eytrasystoles during
this time. Termination of the infusion of ouabain, however, resulted in a further progression
of arrhythmias. In the vehicle treated group, all of the animals developed some kind of
Fig 10. Panel A. The effect of 1 μM ORM-10962 on the delayed afterdepolarization (DAD) amplitude in dog right ventricular Purkinje fibres.
DAD was evoked by a 40 stimulus train with a stimulation cycle length of 400 ms in the presence of 150 nM digoxin. Trace a is a control
recording, trace b indicates the induction of DAD by 150 nM digoxin, and trace c demonstrates that 1 μM ORM-10962 almost completely
abolished DAD. Panel B. Effect of ORM-10962 (1 μM) on digoxin-induced automaticity in dog right ventricular Purkinje fibres. Trace a is a
control recording. Spontaneous activity was recorded after a 40 stimulus train with a stimulation cycle length of 400 ms in the presence of
150 nM digoxin (trace b). Application of 1 μM ORM-10962 in the presence of digoxin abolished the spontaneous activity (trace c).
doi:10.1371/journal.pone.0166041.g010
Table 1. Effect of ORM-10962 (0.3 mg/kg) in ouabain (10 μg/kg/min i.v.) induced arrhythmias in anesthetized (pentobarbitone, 45 mg/kg i.p.)
guinea-pigs. Time of the appearance of ouabain-induced arrhythmias in guinea-pigs.
Group Dose (mg/kg) N VEB (min) VT (min) VF/AVbl(min)
Control - 21 24.0±1.73 31.8±1.85 36.9±1.81
ORM-10962 0.3 11 36.6±2.64 * 40.8±2.17 * 42.4±2.1
Note: N: number of animals in the group; VEB: ventricular extrasystole, bigeminia; VT: ventricular tachycardia; VF/AVbl: ventricular fibrillation or complete
atrioventricular block;
* P<0.05 (see Fig 11A).
doi:10.1371/journal.pone.0166041.t001
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arrhythmia, 3 animals showed ventricular tachycardia and 1 ventricular fibrillation (Table 3
and Fig 11/B). Heart rate and blood pressure could not be determined during this period due
to frequent arrhythmias. After ORM-10962 treatment, the progression of ouabain induced
arrhythmias was less expressed, only 1 animal developed ventricular tachycardia and no ven-
tricular fibrillation occurred. The duration of the arrhythmic period was significantly shorter
and the arrhythmias during this time were not continuous (Table 3 and Fig 11/B).
The lack of effect of ORM-10962 on coronary artery occlusion-reperfusion induced
arrhythmias in rats. In control rats, after coronary artery ligation, arrhythmias appeared at
around the fifth minute of the ischaemia. Coronary artery occlusion of 6 minutes rarely pro-
duced life-threatening arrhythmias, however, reperfusion after ischaemia rapidly induced
severe arrhythmias, frequently leading to the death of the animals. Since the paucity of ischae-
mia induced arrhythmias, only the reperfusion-induced arrhythmias are presented. During
reperfusion after 6 min ischemia 33% of the control animals died due to irreversible
Fig 11. Effect of ORM-10962 (0.3 mg/kg) on ouabain (10 μg/kg/min i.v.) induced arrhythmias in anesthetized (pentobarbitone, 45
mg/kg i.p.) guinea-pigs. Panel A. ORM-10962 was applied as a pre-treatment 10 min before starting permanent ouabain infusion. Mean
time to the development of ventricular arrhythmias is indicated on the Figure. Panel B. ORM-10962 was administered after the termination
of 16 min ouabain infusion. In both Panels the ordinate indicates the numbering of the animals. There was a considerable antiarrhythmic
effect; the duration of arrhythmic periods was shorter under the influence of ORM-10962.
doi:10.1371/journal.pone.0166041.g011
Antiarrhythmic Role of NCX in Cardiac Ventricular Muscle
PLOS ONE | DOI:10.1371/journal.pone.0166041 November 10, 2016 19 / 28
ventricular fibrillation. Other serious arrhythmias e.g. reversible fibrillation (48%) or tachycar-
dia (62%) frequently occurred among the survivors. ORM-10962 pre-treatment did not result
in any change in the development or the severity of these arrhythmias (Table 4 and Fig 12A).
There was no significant difference in heart rate, arterial systolic- and diastolic pressure
among the groups before the coronary artery occlusion. As a result of the occlusion the blood
pressure decreased in all groups. ORM-10962 pre-treatment did not influence significantly the
blood pressure compared to the control group (Table 5).
The lack of effect of ORM-10962 on zero flow ischaemia-reperfusion induced arrhyth-
mias in guinea-pig Langendorff hearts. Zero flow ischemia-reperfusion induced ventricular
fibrillations (VF) were measured in isolated guinea-pig hearts. Several seconds after the start of
reperfusion ventricular fibrillations appeared in both groups. ORM-10962 (1 μM) pre-treat-
ment did not cause a statistically significant difference in the duration of VF, compared to the
control response (42.43± 2.79, n = 7 in controls vs. 45. 56± 4.44 in the presence of drug, n = 9),
(Fig 12B).
Discussion
The most important finding of this study is that the novel NCX inhibitor, ORM-10962, blocks
the NCX current with high efficacy, at well below submicromolar concentrations (calculated
EC50 values are 55/67 nM for inward/outward NCX currents, respectively). The inhibitory
Table 2. Effect of ORM-10962 (0.3 mg/kg) and ouabain (10 μg/kg/min i.v.) in anesthetized (pentobarbitone, 45 mg/kg i.p.) guinea-pigs on the heart
rate and blood pressure.
Group Time (min)
-10 0 2 10 15 17 19 25 30
Control
N 21 21 21 20 18 18 18
HR 259±3.6 255±3.5 255±3.6 272±5.5 289±5 298±5.3 298±5.4
SP 66±2.8 59±1.6 58±1.3 74±2.5 91±4.2 97±4.9 100±4.9
DP 47±2.3 42±1.4 42±1.1 55±2.4 65±3.1 69±3.6 70±3.6
ORM-10962
n 11 11 11 11 10 11 11 9 7
HR 279±5.7 268±4.7 267±4 274±5 280±4.6 285±4.1 290±4.4 306±7.8 315±12.8
SP 56±3.2 51±3 50±2 64±2.8 72±3.4 84±2.3 90±1.9 104±2.9 117±6.2
DP 41±2.8 35±2.2 35±1.6 47±1.8 53±2.9 63±1.8 66±1.4 74±1.4 82±2.6
Note: N: number of the animals at the given time, HR: heart rate (1/min), SP: systolic blood pressure (mmHg), DP: diastolic blood pressure (mmHg), -10
min: baseline values before drug administration, 0 min: starting of the infusion of ouabain (see Fig 11A).
doi:10.1371/journal.pone.0166041.t002
Table 3. Suspension of ouabain induced arrhythmias by ORM-10962, administered after the termination of ouabain infusion (10 μg/kg/min for 16
min) in anesthetized guinea pigs.
Group Dose N Arrhythmic period VEB VT VF/AVbl
(mg/kg) (min) (min) (min) (min)
Control - 10 14.22±2.29 10.5±2.5 0.3±0.2 0.5±0.5
ORM-10962 0.3 12 6.88±1.43 * 5.03±1.3 0.0 0.0
Note: N: total number of animals in the group; Arrhythmic period: Duration between the appearance of the first and the termination of the last arrhythmic
event; VEB: ventricular extrasystole, bigeminia; VT: ventricular tachycardia; VF/AVbl: ventricular fibrillation or complete atrioventricular block;
* P<0.05 (see Fig 11B).
doi:10.1371/journal.pone.0166041.t003
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effect is also highly selective, since even at 20-fold higher concentration the drug had no appar-
ent effect on any of the major transmembrane ion currents determining cardiac action poten-
tial, such as the L-type calcium current, peak and late sodium current, sodium-potassium
pump and the main repolarizing potassium currents (IKr, IKs, Ito and IK1). Selective NCX
Table 4. Effect of ORM-10962 (0.3 mg/kg) on ventricular arrhythmias induced by reperfusion after 6 min coronary artery ligation in anesthetized
(60 mg/kg i.p.) rats.
Groups N Survived Incidence of arrhythmias (n/%) Arrhythmia score
n % None VF VT VEB
Control 21 14 67 1/5 10/48 13/62 8/38 4.00±0.4
ORM-10962 25 17 68 0/0 15/60 14/56 14/56 4.12±0.35
Note: N: total number of animals; n (%): number and percentage of the animals showing the given response; None: animals without any arrhythmia; VF:
ventricular fibrillation; VT: ventricular tachycardia; VEB: ventricular extrasystole and bigeminia (see Fig 12.)
doi:10.1371/journal.pone.0166041.t004
Fig 12. Panel A. Effect of ORM-10962 (0.3 mg/kg) in ischemia-reperfusion induced ventricular arrhythmias during reperfusion after 6 min
coronary artery ligation in anesthetized (pentobarbitone, 60 mg/kg i.p.) rats. Time to the development of ventricular arrhythmias was
measured on the ECG. The ordinates show the numbering of the animals. There was no significant change in the arrhythmias following
administration of ORM-10962. Panel B. Effect of ORM-10962 (1 μM) in global ischemia-reperfusion induced ventricular fibrillation in isolated
guinea pig hearts. ORM-10962 did not influence significantly the duration of ventricular fibrillation.
doi:10.1371/journal.pone.0166041.g012
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inhibition is able to cause positive as well as negative inotropy depending on the actual experi-
mental conditions by changing the operational mode of the NCX. Selective NCX blockade by
ORM-10962 proved to be effective against DAD related arrhythmogenesis, since in vitro
decreased the amplitudes of DADs evoked by digoxin in dog cardiac Purkinje fibres, and in
vivo prevented ouabain induced cardiac arrhythmias in guinea pigs. In contrast, ORM-10962
had no apparent effect on ischaemia-reperfusion induced arrhythmogenesis generated by cor-
onary artery (LAD) occlusion in rats and in Langendorff perfused guinea pig hearts.
Previous studies exploring selective NCX inhibition brought up two major points: the pos-
sible positive inotropic effect which could represent a novel strategy in the treatment of heart
failure and the putative antiarrhythmic effect. Earlier, due to the lack of potent and selective
NCX blockers these hypotheses could not be directly and properly tested. The first promising
and credited “quasi-selective” NCX blockers were KB-R7943 and SEA-0400 [17,18,19,20].
Indeed, both SEA-0400 and KB-R7943 were shown to potently inhibit the NCX current at
micromolar concentration range. In addition, KB-R7943 abolished experimental arrhythmias
[4,15,18,19], while in another previous study we demonstrated that SEA-0400 effectively
decreased the magnitude of both DADs and EADs in dog cardiac preparations [17]. Nonethe-
less, the proposed selectivity of both KB-R7943 and SEA-0400 were seriously questioned by
studies revealing that at micromolar concentrations both blockers inhibit the L-type calcium
current as well [4,15,18,19]. Therefore, in earlier studies the antiarrhythmic effects of NCX
inhibition could not be safely separated from the antiarrhythmic effects of their inhibition of
other transmembrane currents including ICaL. The positive inotropic effect was first tested by
Hobai et al [34] in canine heart failure model applying the NCX inhibitory peptide XIP, which
was able to restore the SR Ca2+ load and release. Ozdemir et al [35] also reported positive ino-
tropic effect of SEA-0400 in a mouse heart failure model. The NCX inhibitor SN-6 has similar
profile to that of SEA-0400, but it is more potent [36]. However, other study questioned its
selectivity and claimed that SN-6 impairs contractility and Ca2+ handling [37]. The results of
earlier NCX inhibitors were briefly summarized by Antoons et al. [20].
Recently, electrophysiological effects of another novel NCX inhibitor ORM-10103 were
studied in vitro at the cellular level [21]. This compound also effectively blocked both forward
and reverse NCX currents at concentrations close to 1 μM (estimated EC50 values are 780 nM
and 960 nM, respectively). Contrary to ORM-10962, ORM-10103 had a small inhibitory effect
on IKr. Furthermore, it has not been tested in an in vivo arrhythmia model as yet.
Table 5. Effect of ORM-10962 (0.3 mg/kg) on the heart rate and blood pressure during ischaemia and reperfusion in anesthetized (60 mg/kg i.p.)
rats.
Time of ischaemia (min) Time of reperfusion (min)
Group N -10 0 1 3 5 N 1 3 5
Control
HR 21 427±9.0 410±9.0 415±10.3 418±10.9 415±11.4 14 416±10.9 407±13.1 417±13.4
SP 108±2.3 107±2.3 78±2.6 81±3.4 84±3.6 89±8.5 95±7.6 94±6.6
DP 71±3.4 71±3.4 44±2.0 48±2.6 53±3.3 55±7.7 61±7.9 59±7.0
ORM-10962
HR 25 411±8.5 397±8.2 410±9.6 404±9.4 401±10.7 17 387±14.5 400±10.1 384±15.0
SP 105±3.0 109±3.2 84±3.6 87±3.3 90±3.4 88±6.1 94±7.2 100±8.8
DP 73±3.3 77±3.7 54±2.8 58±2.7 61±3.0 56±5.2 64±6.9 69±7.5
Note: N: total number of animals, HR: heart rate (1/min), SP: systolic blood pressure (mmHg), DP: diastolic blood pressure (mmHg), -10 min: drug
administration, 0 min: starting of the coronary artery occlusion (see Fig 12).
doi:10.1371/journal.pone.0166041.t005
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In this previous study, inhibition of NCX by ORM-10103, another inhibitor, effectively pre-
vented the strophantidine-induced Ca2+ accumulation and spontaneous diastolic Ca2+ releases
when used as a pre-treatment. This was interpreted as a consequence of reverse mode inhibi-
tion [38]. Similarly, in the present study, ORM-10962 pre-treatment delayed the appearance of
arrhythmias in in vivo guinea pig experiments (Fig 11A) that could be the consequence of
reverse mode inhibition. In addition, when ORM-10962 was applied after intracellular Ca2+
overload and arrhythmias are already established (Figs 10 and 11B) the antiarrhythmic effect
of NCX inhibition can be explained partially by forward mode inhibition resulting in less
depolarization and thereby eliminating DAD’s in Purkinje fibres and suppressing arrhythmias
in guinea-pig experiments.
The selective NCX inhibition exerts slight positive inotropy under normal
condition
Theoretical assumptions [5,7,12] as well as experimental results [38,39] suggest that in mam-
malian cardiomyocytes with long action potential plateau, the NCX mainly operates in for-
ward mode extruding Ca2+ ions from the cell. Thus, theoretically, the decreased rate of Ca2+
extrusion may lead to net gain of the intracellular Ca2+ causing positive inotropy, while the
reduced inward NCX current may shorten the action potentials [5,7,12]. In “physiological”
NCX operational mode we found slightly increased Ca2+ transient amplitude and moderately
enhanced cell shortening after selective NCX inhibition which supports the theory of slight
Ca2+ accumulation. However, we failed to prove the change of action potential waveform (Fig
8). Our results may indicate an increase of the SR Ca2+ content without changes of the diastolic
Ca2+ level. In our previous study, we characterized the NCX current during an action potential
as an ORM-10103-sensitive current [38]. Since this current had relatively small amplitude we
suggest that under normal circumstances the NCX current has marginal role in shaping the
action potential. Furthermore, this small change may be compensated for other repolarizing
currents. These results may also suggest that during a cardiac cycle similar extent of Ca2+ gain
and loss should be expected by the operation of NCX. In other words, in physiological condi-
tions the NCX inhibition is resulted in less intracellular Ca2+ and contractility changes than
was previously believed. Therefore, the effect of NCX inhibition should be carefully studied in
the future in different pathophysiological situations (ischaemia, heart failure, etc.) when NCX
operational mode can be different from those in the normal “physiological” situation.
Positive and negative inotropic effect of ORM depends on the actual
operational mode of NCX
In contrast with the small positive inotropic effect of ORM-10962 found in this study (Fig 8),
in our previous paper we described negative inotropic effect of selective NCX inhibition using
ORM-10103 after 2 nM ATX application [38]. These disparate results suggested that NCX
inhibition could equally lead to positive and negative inotropy depending on the actual NCX
reversal potential. This study showed that the ATX-induced Na+ accumulation can markedly
increase the ratio of the reverse mode—and thus NCX-mediated Ca2+ influx—which inhibi-
tion may have crucial role in the observed negative inotropy. In line with this, when [Na+]o
was reduced to 70 mM in this study, the reversal potential may shifted toward more negative
range enhancing the contribution of the reverse mode to establish a new equilibrium. Thus,
under this condition the NCX inhibition decreases the Ca2+ transient amplitude and cell short-
ening presumably via the suppression of the reverse mode.
In parallel experiments we intended to facilitate the NCX forward mode by applying forsko-
lin to increase the adenylate-cyclase activity. We assume that the increase of the intracellular
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Ca2+ level without major rise of the intracellular Na+ may shift NCX reversal potential toward
more positive values promoting forward mode activity. In this setting the observed positive
inotropy may reflect further increase of SR Ca2+ content by reduction of the NCX mediated
Ca2+ extrusion.
These data have led us to the conclusion that selective NCX inhibition may have negative
inotropic and antiarrhythmic effect, when Ca2+ load is coupled with marked increase of intra-
cellular Na+ and, this condition may facilitate the reverse mode activity of the NCX. This
hypothesis was tested in dog Purkinje fibers where NCX inhibition almost completely abolished
the digoxin induced DADs (see Fig 10). Under this setting the NCX inhibition may reduce the
SR Ca2+ level primarily via the inhibition of reverse mode mediated Ca2+ influx, thus the for-
ward mode may be indirectly reduced, following the decreasing intracellular Ca2+. Thus, we
assume that the termination of DADs depicted in Fig 10, is a consequence of an indirect inhibi-
tion of the forward mode achieved by the decreased Ca2+ level caused by reverse mode inhibi-
tion, but some contribution of forward mode inhibition cannot be entirely ruled out.
It is worth mentioning that Ca2+ transients and cell shortening have somewhat different
relaxation kinetics. The difference was not consistent and thereby statistically not significant.
The exact reason for this discrepancy is not clear. Indirect Ca2+ sensitizing effect by ORM-
10962 on the myofilaments cannot be ruled out. Also, Ca2+ transients reflect Ca2+ changes in
the bulk of the cytosol which can differ from those of the subsarcolemmal space and in the
close vicinity of the myofilaments.
NCX inhibition is effective against ouabain arrhythmias but failed during
ischemia-reperfusion induced arrhythmias
The selective NCX inhibition during in vivo ouabain-induced arrhythmias (Fig 11) in guinea
pigs provided similar results compared with those we observed during digoxin-induced DADs
in Purkinje fibers (Fig 10). We suggest that the underlying mechanism could be also similar:
the antiarrhythmic effect may be based on the decreased intracellular Ca2+ level after inhibi-
tion of the reverse mode activity. Nevertheless, the role of some indirect NCX inhibition can-
not be entirely excluded either. In contrast, ORM-10962 failed to reduce the arrhythmia
incidence during ischaemia-reperfusion in rat in vivo (Fig 12A) and in guinea-pig in vitro (Fig
12B), even though several papers claimed the efficiency of NCX inhibition during ischaemia-
reperfusion [15,40,41,42,43]. Interestingly, only some studies [44,45,46,47] were performed
under in vivo conditions. Only one paper described antiarrhythmic effect of SEA0400 [46], the
other studies reported failure of NCX inhibition (SEA-0400 and KB-R7943) to reduce arrhyth-
mia incidence in vivo. Furthermore, in these studies SEA-0400 and KB-R7943 were used in
such high concentration, which also inhibit the ICaL current making the interpretation of the
data more difficult. A previous study from our laboratory [48] reported lack of antiarrhythmic
effect of ORM-10103 against ischaemia-reperfusion induced arrhythmias in Langendorff-per-
fused rats. The failure of NCX under this setting could be explained by the fact that the devel-
opment of arrhythmias in ischaemia-reperfusion are rather complex phenomena involving
several different mechanisms such as reentry, spontaneous automacy, DADs etc [49], and the
NCX may not have important role in each mechanism. Furthermore, the lack of effect in rat as
well as in guinea pigs may rule out the species dependent antiarrhythmic effect of selective
NCX inhibition.
Study limitations
We suggested that the antiarrhythmic action of NCX inhibition is mainly achieved by inhibi-
tion of the reverse mode and partially by suppression of the forward mode. This interpretation
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is based on speculations relating to our Ca2+ transient data and by considering our previous
results [38]. However, the exact evaluation of the antiarrhythmic mechanism of NCX inhibi-
tion requires further experiments analyzing the effect of ORM-10962 on Ca2+ cycling and SR
Ca2+ load in detail especially during pathological condition. Other possible limitation regard-
ing the selectivity of ORM-10962 can be that we only studied its effects on transmembrane ion
currents at fixed, relatively low intracellular Ca2+ concentrations. During the action potential,
however, both intracellular Ca2+ and Na+ concentrations change markedly and dynamically.
In theory, these changes can largely influence drug binding and consequently the efficacy of
the compound on 2a variety of sarcolemmal ion channels. Another limitation concerns the
possible role of NCX in arrhythmogenesis. These experiments were carried out in healthy,
undiseased myocardium and in an acute ischemia model in the rat and in isolated guinea pig
hearts. Arrhythmogenesis frequently occurs in diseased hearts (e.g. in heart failure, during
chronic myocardial ischemia, etc.) in which calcium handling and NCX function may substan-
tially differ from their state in healthy hearts, or following acute coronary ligation in hearts of
otherwise healthy animals. Furthermore, species other than rat, having differing Ca2+-handling
mechanisms, may respond differently to NCX inhibition in ischemia/reperfusion induced
arrhythmias. Therefore, a number of further studies are needed to explore the potential thera-
peutic value of NCX inhibition in cardiac arrhythmogenesis.
Conclusions and Clinical Implication
To our knowledge ORM-10962 is the first reported compound that can inhibit both forward
and reverse NCX currents at well below submicromolar concentrations without affecting fur-
ther essential sarcolemmal transport mechanisms. Selective NCX inhibition also exerts potent
antiarrhythmic effect in digitalis induced arrhythmias. The previously reported antiarrhythmic
effect of moderately selective compounds in ischemia/reperfusion induced arrhythmogenesis
can be seriously questioned. While we suggest that selective NCX inhibition may have thera-
peutic implications by counteracting triggered automaticity, further detailed studies are
needed before its cardioprotective role can be properly established.
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